Edition:
United States

Acceleron Pharma Inc (XLRN.A)

XLRN.A on American Stock Exchange

36.59USD
20 Oct 2017
Change (% chg)

$-0.74 (-1.98%)
Prev Close
$37.33
Open
--
Day's High
$36.59
Day's Low
$36.59
Volume
217
Avg. Vol
--
52-wk High
$39.96
52-wk Low
$31.48

Select another date:

Wed, Sep 20 2017

BRIEF-Acceleron announces pricing of public offering of common stock

* Acceleron announces pricing of public offering of common stock

BRIEF-Acceleron announces proposed public offering of common stock

* Acceleron announces proposed public offering of common stock

BRIEF-Acceleron Pharma Q2 loss per share $0.77

* Acceleron Pharma reports second quarter 2017 operational and financial results

BRIEF-Acceleron announces first patient treated in phase 2 clinical trial of ACE-083

* Acceleron announces first patient treated in phase 2 clinical trial of ACE-083 in Charcot-Marie-Tooth disease Source text for Eikon: Further company coverage:

BRIEF-Acceleron announces top-line results from dart phase 2 study of dalantercept

* Acceleron announces top-line results from dart phase 2 study of dalantercept in advanced renal cell carcinoma

BRIEF-Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept

* Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia

BRIEF-Acceleron Pharma qtrly loss per share $0.66

* Acceleron pharma reports first quarter 2017 operational and financial results

BRIEF-Acceleron announces management change

* Acceleron Pharma Inc - Steven Ertel, due to medical reasons, will transition from his role as executive vice president and chief operating officer

BRIEF-Acceleron says enrolment for late stage studies now expected to be completed in Q2

* Acceleron provides clinical development updates on luspatercept program

Select another date: